Qian Ning1, Yang Wang1, Yi Zhang1, Guozhi Shen1, Zhenglu Xie1,2, Jie Pang3. 1. Jinshan College of Fujian Agriculture and Forestry University, Fujian Province, 350001, P. R. China. 2. Collaborative Innovation Center of Animal Health and Food Safety Application Technology in Fujian, Fujian Vocational College of Agriculture, Fuzhou City, Fujian Province, 350002, P.R. China. 3. College of Food Science, Fujian Agriculture and Forestry University, Fujian Province, 350001, P. R. China.
Abstract
OBJECTIVE: This study investigatesthe nuciferine capacity to regulate the liver's lipid metabolism regarding steatosis and injury in STZ-induced diabetic rats. MATERIALS AND METHODS: The rats were randomly divided into groups control, diabetic and nuciferine 200 mg/kg/ day treatment. After 4 days of STZ injection, the nuciferine group was treated and administered via oral gavages for 4 weeks. At the end of experiment, blood, liver, myocardial and muscular samples were collected. RESULTS: Nuciferine-treated significantly increased the body weight from 339.4g to 367.8g, but significantly decreased the food and water intake compared with diabetic rats. Also, the nuciferine-treated rats had significantly decreased TC, TG, and FFAs in the liver compared with the diabetic group, especially the serum markers of blood glucose. These were associated with the gene expression related to lipogenesis which was significantly down-regulated; the gene expression involved in lipolysis and fatty acid β-oxidation was significantly up-regulated. Discussion and. CONCLUSION: The data provide evidence that nuciferine supplementation could protect the liver by regulating lipid metabolism gene expression resulting in decreasing the steatosis and injury in diabetic rat. Thus, nuciferine could be developed as a diabetic adjuvant food additive in future.
OBJECTIVE: This study investigatesthe nuciferine capacity to regulate the liver's lipid metabolism regarding steatosis and injury in STZ-induced diabetic rats. MATERIALS AND METHODS: The rats were randomly divided into groups control, diabetic and nuciferine 200 mg/kg/ day treatment. After 4 days of STZ injection, the nuciferine group was treated and administered via oral gavages for 4 weeks. At the end of experiment, blood, liver, myocardial and muscular samples were collected. RESULTS: Nuciferine-treated significantly increased the body weight from 339.4g to 367.8g, but significantly decreased the food and water intake compared with diabetic rats. Also, the nuciferine-treated rats had significantly decreased TC, TG, and FFAs in the liver compared with the diabetic group, especially the serum markers of blood glucose. These were associated with the gene expression related to lipogenesis which was significantly down-regulated; the gene expression involved in lipolysis and fatty acid β-oxidation was significantly up-regulated. Discussion and. CONCLUSION: The data provide evidence that nuciferine supplementation could protect the liver by regulating lipid metabolism gene expression resulting in decreasing the steatosis and injury in diabetic rat. Thus, nuciferine could be developed as a diabetic adjuvant food additive in future.
Authors: Heather Basciano; Abigale E Miller; Mark Naples; Christopher Baker; Rita Kohen; Elaine Xu; Qiaozhu Su; Emma M Allister; Michael B Wheeler; Khosrow Adeli Journal: Am J Physiol Endocrinol Metab Date: 2009-06-09 Impact factor: 4.310